type 2 inflammation

Connect Biopharma Advances Rademikibart Toward Phase 3

SAN DIEGO, Calif. — September 15, 2026 Connect Biopharma Holdings Limited announced positive preliminary topline results from the global...

By cGxPwire Editor
September 16, 2026

Bio-Pharma

Kymera Therapeutics Advances KT-621 in Atopic Dermatitis

WATERTOWN, Mass., Sept. 1, 2026 Kymera Therapeutics, Inc. has announced upcoming presentations featuring clinical data for KT-621, its first-in-class...

By cGxPwire Editor
September 2, 2026

Bio-Pharma

Bambusa Reports Promising BBT002 Data for COPD Therapy

BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary multiple ascending dose (MAD) Phase 1 clinical data for...

By cGxPwire Editor
July 20, 2026

.Clinical

Bambusa Therapeutics Reports Positive Phase 1 BBT002 Data at EAACI 2026

BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of...

By cGxPwire Editor
June 16, 2026

Pharma

Japan Approves Dupixent for Children With Severe Asthma

TOKYO, Japan — December 23, 2025 — The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval...

By cGxPwire Editor
December 23, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory